GIPTIS (Genetics Institute for Patients, Therapies, Innovation & Science)
Created in 2017
Social networks
699 989Activities
Entity types
Location
61 Bd des Dames, 13002 Marseille, France
Marseille
France
Employees
Scale: 2-10
Estimated: 1
Engaged corporates
2
2 2Added in Motherbase
2 years, 9 months ago
biotech Value proposition
The majority of rare diseases are chronic disorders which are most often of genetic origin (in 80% of the cases) and mainly affect children (60%). Each disease is rare (1/2000 person), but together the rare disorders affect around 6-8% of the general population.
The number of people suffering from rare diseases is estimated to be around 3 million in France, 50 million in the Mediterranean Basin, 25 to 30 million in Europe and 27 million in North America. But Less than 5 % of patients receive an adapted treatment!
A new healthcare model > GIPTIS (Genetics Institute for Patients, Therapies, Innovation and Science)
GIPTIS reinvents healthcare’s organizational model by placing patients affected with rare disease at the heart of a care and research loop to accelerate drug development, using an unprecedented public-private cooperation. The 3 main goals are:
• Reduce diagnostic wavering
• Improve global patient care
• Reduce the drug development period to less than 10 years
GIPTIS will gather in an unique place at the cutting edge of technology: private companies deeply associated to research projects, international & high potential researchers, healthcare professionals, technological resources centers, in-house support and drug development
departments.
The covered expertises will be:
• From developmental biology to genetics of rare diseases
• From epigenetics to genomes dynamics
• From bioinformatics to system and integrative biology
génétique and maladies raresOriginal language
The majority of rare diseases are chronic disorders which are most often of genetic origin (in 80% of the cases) and mainly affect children (60%). Each disease is rare (1/2000 person), but together the rare disorders affect around 6-8% of the general population.
The number of people suffering from rare diseases is estimated to be around 3 million in France, 50 million in the Mediterranean Basin, 25 to 30 million in Europe and 27 million in North America. But Less than 5 % of patients receive an adapted treatment!
A new healthcare model > GIPTIS (Genetics Institute for Patients, Therapies, Innovation and Science)
GIPTIS reinvents healthcare’s organizational model by placing patients affected with rare disease at the heart of a care and research loop to accelerate drug development, using an unprecedented public-private cooperation. The 3 main goals are:
• Reduce diagnostic wavering
• Improve global patient care
• Reduce the drug development period to less than 10 years
GIPTIS will gather in an unique place at the cutting edge of technology: private companies deeply associated to research projects, international & high potential researchers, healthcare professionals, technological resources centers, in-house support and drug development
departments.
The covered expertises will be:
• From developmental biology to genetics of rare diseases
• From epigenetics to genomes dynamics
• From bioinformatics to system and integrative biology
